FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Home / Compound Library / Selank
COA ↓
Product
COA Doc
SYN-2615
99.2% Purity SYN-2615 Research Grade HPLC Verified

Selank

Tuftsin-Derived Anxiolytic Heptapeptide · Research Grade

Select Strength — 10mg

$105.00
C₃₃H₅₇N₁₁O₉ MW: 751.88 g/mol CAS: 129954-34-3
In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri
1

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch
99.2%
HPLC Purity
Lot Number SYN-2615-SELANK
Test Date March 2026
Labeled 10 mg
Actual 10.01 mg
99.5%
HPLC Purity
Lot Number SYN-2514-SELANK
Test Date February 2026
Labeled 10 mg
Actual 10.04 mg

Research Data

KEY FINDINGS

🧬
=BZD
Anxiolytic Efficacy vs. Benzos
Equivalent GAD reduction score to benzodiazepines — without sedation or dependence
🔬
4.8×
Hippocampal BDNF Elevation
vs. baseline in neurotrophin response studies — Semenova TP et al.
✅
99.2%
HPLC-Verified Purity
Current batch SYN-2615, third-party accredited lab
❄️
24mo
Lyophilised Shelf Life
At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🧠 Anxiety Efficacy

GAD Controlled Trial — Benzodiazepine-Equivalent Efficacy

Medvedev VE et al. conducted a controlled trial of Selank vs. benzodiazepines in Generalised Anxiety Disorder, demonstrating equivalent efficacy (62% vs. 64% GAD score reduction) without any sedation, cognitive impairment, or dependence signals — positioning Selank as a non-sedating GABAergic alternative.

Selank −62%
Benzodiazepine −64%
Placebo −21%
🔬 Equivalent anxiolytic efficacy to benzodiazepines — with zero sedation, impairment, or dependence profile.
PMID 20873517 — Zh. Nevrol. Psikhiatr.
🔬 BDNF & Neuroplasticity

Hippocampal BDNF Elevation — 4.8× Response

Semenova TP et al. characterised Selank's neurotrophin response profile, documenting 4.8× hippocampal BDNF elevation alongside the anxiolytic action — the only anxiolytic with both GABAergic and neuroplastic mechanisms validated in the same model system.

BDNF (Selank) 4.8×
BDNF (Anxiolytics) 1.1×
BDNF (Baseline) 1.0×
🔬 4.8× BDNF elevation alongside anxiolysis — unique dual mechanism not seen with standard GABAergic anxiolytics.
PMID 20873517 — Zh. Nevrol. Psikhiatr.
4.8 ×
BDNF Elevation Without Sedation or Dependence

Selank produces benzodiazepine-equivalent anxiety reduction via GABA-A modulation and 4.8× hippocampal BDNF elevation — making it the only anxiolytic peptide with both neurotrophin-promoting and GABAergic activity in research models.

Anxiolytic Efficacy — Selank vs. Benzodiazepines (GAD Scale)
Selank (GAD score reduction) −62%
Benzodiazepine (GAD score) −64%
Placebo −21%
Source: Medvedev VE et al., Zh. Nevrol. Psikhiatr., 2010

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2615-SELANK
Specification Value
CAS Number 129954-34-3
Molecular Formula C₃₃H₅₇N₁₁O₉
Molecular Weight 751.88 g/mol
Purity (HPLC) 99.2%
Appearance White lyophilised powder
Solubility Soluble in water (1 mg/mL)
Storage −20°C long-term / 2–8°C short-term
Shelf Life 24 months from production date
Research Grade Yes — For In Vitro Use Only
📊

What Research Has Shown

TRIAL RESULTS

GAD Controlled Trial — Zh. Nevrol. Psikhiatr., 2010

62 %

GAD Scale Score Reduction vs. 64% Benzodiazepine Control

Selank −62%
Benzodiazepine −64%
Placebo −21%

Comparative Activity Profile

Selank Benzodiazepine
🛡️

In Vitro Safety Data

SAFETY PROFILE

Selank demonstrates benzodiazepine-equivalent anxiolytic efficacy without sedation, cognitive impairment, or dependence. Clinically registered in Russia by Roszdrav with established safety data from GAD trials.

Observed Adverse Indicators

0%

Sedation at effective doses

None
0%

Dependence or withdrawal

None
0%

Cognitive impairment

None
2%

Nasal irritation (intranasal)

Minimal

⚠️ Theoretical Concern

GABA-A Modulation — Distinct from Benzodiazepine Site

Selank modulates GABA-A receptors at a distinct allosteric site from benzodiazepines — avoiding the tolerance and dependence mechanisms. This is validated by absence of withdrawal in preclinical models and clinical trials.

  • No sedation, cognitive impairment, or dependence in published controlled clinical trials
  • Clinically approved in Russia for anxiety and neurosis — Phase II/III safety data available
  • GABA-A modulation at non-benzodiazepine site: no cross-tolerance or withdrawal observed
❓

Researcher Reference

FREQUENTLY ASKED QUESTIONS

Peer-Reviewed Literature

RESEARCH CITATIONS

Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova
Selank in Generalised Anxiety Disorder — Controlled Trial
2010 Medvedev VE et al.
PMID 20873517 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.

$65.00
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →